BlossomHill Therapeutics, Inc.

BLSM Nasdaq SEC CIK 1839970
Follow BlossomHill Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$24M −50.3% vs same quarter last year
EPS, diluted −$1.29 +80.3% vs same quarter last year
Operating cash flow −$22.2M −91.6% vs same quarter last year
Operating income −$25.5M −52.3% vs same quarter last year
Net income by quarter
−$13.2M
−$16M
−$23.8M
−$24M
Q2 25 Q3 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing